Pimozide , 10mMinDMSO , 2062-78-4

Synonym(s):
1-(1-(4,4-Bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one;1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one;STAT5 Inhibitor III, Pimozide - CAS 2062-78-4 - Calbiochem

CAS NO.：2062-78-4

Empirical Formula: C28H29F2N3O

Molecular Weight: 461.55

MDL number: MFCD00055081

EINECS: 218-171-7

PRODUCT Properties

• Melting point: 214-218°
• Density: 1.1763 (estimate)
• storage temp.: 2-8°C
• solubility: DMSO: 18 mg/mL
• pka: 7.32(at 25℃)
• form: White solid
• color: Off-White to Light Orange
• Water Solubility: 2.9mg/L(30 ºC)

Description and Uses

Pimozide is a dopamine receptor antagonist (Kis = 2.4, 0.3, and 1.8 nM for D2, D3, and D4 receptors, respectively). It also binds to eight additional receptors (Kds = 25-3,100 nM for the human receptors) and inhibits the voltage-gated sodium channel Nav1.2 and the voltage-gated potassium channel Kv11.1 (IC50s = 42 and 340 nM, respectively). Pimozide (0.5, 1, and 2 mg/kg) decreases the number of licks and reduces fluid intake of a sweetened solution in rats. It decreases the number of threats and attacks and increases immobility time in the neutral arena aggression test, indicating increased passiveness, in male mice when administered at a dose of 0.75 mg/kg for 10 days. Formulations containing pimozide have been used in the treatment of Tourette syndrome.

Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: Xn
• Risk Statements: 22
• Safety Statements: 36
• RIDADR: 3249
• WGK Germany: 3
• RTECS: DE1750000
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 2933399090